Serum aspartate aminotransferase, a novel potential biomarker of prognosis in extranodal natural killer/T cell lymphoma, nasal type.
Cancer Biomark
; 39(4): 265-275, 2024.
Article
en En
| MEDLINE
| ID: mdl-38108343
ABSTRACT
BACKGROUND:
Aspartate aminotransferase (AST), an indicator of liver cell damage, was related to the prognosis of certain malignant tumors.OBJECTIVE:
This study examined the predictive value of AST in patients with extranodal natural killer/T cell lymphoma (ENKTL).METHODS:
We reviewed 183 cases diagnosed with ENKTL and selected 26 U/L as the optimum cut-off value of AST. We used the univariate and multivariate Cox regression to compare the different AST groups' overall survival (OS) and progression-free survival (PFS).RESULTS:
Prior to propensity score matching (PSM), Kaplan-Meier analysis showed that patients in the low AST subgroup had better OS and PFS than the high AST subgroup. Multivariate analysis revealed that AST was an independent indicator for prognosis. After PSM, the low AST subgroup maintained a significantly better OS and PFS than the high AST subgroup.CONCLUSION:
AST might represent a significant prognostic marker for ENKTL patients.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Aspartato Aminotransferasas
/
Biomarcadores de Tumor
/
Linfoma Extranodal de Células NK-T
Límite:
Adolescent
/
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Cancer Biomark
Asunto de la revista:
BIOQUIMICA
/
NEOPLASIAS
Año:
2024
Tipo del documento:
Article
País de afiliación:
China